A Helium Company Listed Through a Liver-Disease Shell

ASP Isotopes is presenting at a natural resources conference next week in Las Vegas. That is the press release that came out today, and it is not what is happening here. The actual story is that ASP Isotopes is trying to turn itself into a collection of separate public companies because, at $4.18 a share, the market is not giving the parent holding company the valuation that management wants.

The most revealing detail in that effort came in June. ASP Isotopes announced that its helium subsidiary, Renergen, would merge with ENDRA Life Sciences - a company that develops thermoacoustic imaging for fatty liver disease - to create a new Nasdaq-listed helium platform called Noble Africa. The liver-disease company is the vehicle. The helium project is the cargo. ASPI will own roughly 89% of the combined entity, with a concurrent $50 million private placement funding Phase 1 and Phase 2 development of the Virginia Gas Project in South Africa.

A natural resources company listing its helium business through a biomedical shell company is the sort of thing that happens when your actual revenue is $3.7 million a quarter and your annual cash burn is $70 to $80 million, and you still need the market to take you seriously.

The basic point is that ASP Isotopes is running what amounts to a five-part spinout operation. PET Labs, the radiopharmacy unit, is the only segment with real revenue - it grew 50% organically in the first half of 2026 and is forecast to hit roughly $14 million this year. Renergen, the helium and LNG business, is going public via the ENDRA reverse merger. Quantum Leap Energy, the nuclear fuels subsidiary, is pursuing its own separate public listing. Alpa Theranostics, a newly established biotech company using nanobodies conjugated to radioisotopes, is advancing toward clinical trials. And the stable isotope enrichment business - the one closest to the company's original name - is in the "final stages" of commercial production and expects to ship silicon-28 and ytterbium-176 in the second half of 2026.

That last one is worth pausing on. Deliveries of silicon-28 under the company's largest-ever supply contract were expected in the first quarter of 2026. The CEO's August 4 shareholder letter says they are now expected in the second half. The explanation is equipment performance issues from former OEM suppliers, not issues with ASP's own enrichment technology. The CEO says the core technology continues to perform in line with theoretical models. I am willing to take that at face value, but theoretical models and shipped product are different things, and the gap between them has already consumed a full quarter.

So here is what the machine actually is. ASP Isotopes raised $210 million in October 2025 by selling over 17 million shares at $12.25 each. The stock is now at $4.18 - down roughly 66% from the raise price. The parent is burning through cash at a pace that makes a 2031 target of $300 million in EBITDA look like an aspiration written in permanent marker rather than a roadmap. The response to this arithmetic is not to consolidate or right-size; it is to break the company into pieces and give each one its own public listing so investors can apply different multiples to each business.

The helium spinoff via the ENDRA merger is the most instructive example of the plumbing. Under the deal terms, ASP Isotopes gets six of the six board seats on Noble Africa, including the CEO. Pre-closing ENDRA shareholders get 3% of the combined company. Outside private placement investors get 7%. The remaining 89% stays with ASPI. That is a reverse merger in which the parent retains nearly all the equity and all the governance control. The shell company provides the Nasdaq listing and the registration statement infrastructure. The outside capital - $30 million from third parties and $750,000 from ASPI's own directors and management - provides the development cash. It is a clever structure, but it is also a way of converting a private helium development project into a publicly tradable asset without actually selling any of the parent's ownership.

The same impulse is happening with Quantum Leap Energy, the nuclear fuels subsidiary, which is now pursuing an independent public listing. The CEO's letter mentions a potential future distribution of QLE shares to ASPI stockholders in a "tax-efficient manner" - in other words, a spinoff. So ASPI shareholders would eventually hold a piece of the nuclear fuels business directly, rather than through the parent holding company.

The idea here is not wrong in principle. Conglomerates trade at a discount. If you can separate a radiopharmacy, a helium platform, a nuclear fuels developer, a stable isotope producer, and a biotech company into distinct entities, each one could theoretically command a multiple appropriate to its sector. That is the sum-of-the-parts pitch, and it is one of the oldest valuation tricks in the book.

The problem is that the parts are not yet parts. They are capital consumption projects. PET Labs is the only one generating material revenue, and even at the forecast $14 million for 2026, it is not close to the $50–100 million of EBITDA management expects by 2031. Renergen has $750 million in committed debt financing from sources including the U.S. Development Finance Corporation, but helium production is not expected to begin until before September 30, 2026 at the earliest, and those are forecast revenues, not contracted ones - although management says it is negotiating take-or-pay arrangements on 5- to 15-year terms. The enrichment facilities are slipping. And the biotech arm is pre-clinical.

There is also the question of what ASPI looks like after it gives most of its businesses away. If Renergen goes public as Noble Africa, if Quantum Leap Energy lists separately, and if the biotech unit eventually gets carved out, what is left inside the parent? The stable isotope business, which has already missed one delivery deadline, and a license-royalty stream from the businesses it created and is now distributing. The holding company would become, in effect, a royalty wrapper around the things it built.

The Citi Natural Resources Conference next week is where the company gets to present this plan to investors in person. The capital markets day on September 8 will be the deeper dive. But the structural question is not about timing or investor access - it is about whether a holding company that is burning $70–80 million a year can credibly spin off its best assets into separate public companies while the parent retains enough substance to justify its own valuation.

The simplest model is this: if every subsidiary reaches its stated target, the sum of the parts is enormous. If even two of them slip, as the silicon-28 deliveries already have, the cash burn at the parent becomes the dominant feature of the story, and the spinoff strategy looks less like value creation and more like a way to move the dilution problem into separate buckets. The shareholders who bought in at $12.25 are already holding the difference.

I don't know whether the helium project will come online on schedule, or whether the enrichment technology will ship product in 2H 2026, or whether the nuclear fuels licensing will ever generate more than a line item. What I do know is that the structure itself - the reverse mergers, the planned spinoffs, the tax-efficient distributions - is doing a lot of work to make a speculative portfolio of development projects look like a diversified industrial platform. That is not a critique of the strategy. It is an observation about what the plumbing is actually doing.

The conference participation is boilerplate. The shareholder letter is optimistic. The real question is whether the pieces can survive independently once they are separated from the parent that has been funding their development. If they can, the spinoff plan is smart. If they can't, the company has just taken one expensive holding structure and turned it into five smaller ones.